Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Fluasterone buccal tablet crossover study in hyperglycemia associated with endogenous Cushing syndrome
2023-508322-10-00Phase 2Authorised
- Sponsor
- SteroTherapeutics
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, double-blind trial of fluasterone in Cushing's syndrome (2 arms), sponsored by SteroTherapeutics. Primary endpoint: Change in glucose area under the curve at week 12. Planned start May 2025; status: authorised.
02
Drugs
fluasterone
03
Conditions
Cushing's syndrome
Beyond the preview
Go deeper on 2023-508322-10-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2023-508322-10-00.